QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ambizas, E. M Articles by Ginzburg, R. Search for Related Content PubMed PubMed Citation Articles by Ambizas, E. M Articles by Ginzburg, R.

NEW DRUG APPROVALS

Lubiprostone: A Chloride Channel Activator for Treatment of Chronic Constipation

Assistant Clinical Professor, College of Pharmacy & Allied Health Professions, St John's University; Clinical Specialist, Brooks Eckerd Pharmacy, Queens, NY

Regina Ginzburg, PharmD

Assistant Clinical Professor, College of Pharmacy & Allied Health Professions, St. John's University; Ambulatory Pharmacy Faculty, Beth Israel Residency in Urban Family Practice—Institute for Urban Family Health; Clinical Instructor, Albert Einstein College of Medicine, New York, NY

Reprints: Dr. Ambizas, College of Pharmacy & Allied Health Professions, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, fax 718/990-1986, arweilee{at}stjohns.edu

OBJECTIVE: To review lubiprostone's pharmacology, pharmacokinetics, efficacy, and safety in the treatment of chronic constipation.

DATA SOURCES: A literature search was conducted using PubMed/MEDLINE (1966–January 2007), IngentaConnect, and International Pharmaceutical Abstracts (1977–January 2007). Key words used included lubiprostone, Amitiza, and chronic constipation.

STUDY SELECTION AND DATA EXTRACTION: All articles identified from the data sources that were published in English were evaluated.

DATA SYNTHESIS: Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours. Phase III trials have noted that most patients with chronic constipation have a spontaneous bowel movement within 24 hours after taking lubiprostone. The most common adverse events in these trials were nausea, diarrhea, abdominal pain, and headache. Lubiprostone use has not been studied in the pediatric population.

CONCLUSIONS: Lubiprostone may be a reasonable alternative for use in patients who either fail or are intolerant of standard therapy for chronic constipation. Head-to-head comparison studies with conventional therapy are needed to contrast clinical efficacy and safety of this medication.

Key Words: Amitiza, chronic constipation, lubiprostone

Published Online, May 22, 2007. www.theannals.com, DOI 10.1345/aph.1K047

This article has been cited by other articles:

				K. E. Barrett New ways of thinking about (and teaching about) intestinal epithelial function Advan Physiol Educ, March 1, 2008; 32(1): 25 - 34. [Abstract] [Full Text] [PDF]